On October 12, 2020 Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) reported a poster presentation at the 32nd EORTC-NCI-AACR (Free EORTC-NCI-AACR Whitepaper) Symposium on Molecular Targets and Cancer Therapeutics to be held October 24-25, 2020 in a virtual format (Press release, Sunesis, OCT 12, 2020, View Source [SID1234568324]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The details for the poster presentation are as follows:

Date and Time: October 24, 2020, 9:00 a.m. ET
Abstract Title: PDK1 inhibitor SNS-510 shows synergy with standard cancer therapies in solid tumor and hematologic cancer models
Session Name: Molecular Targeted Agents
Publication Number: 163

The full abstract can be viewed here, and the poster will be made available on the Sunesis website at the time of the presentation.